EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China

Jiangong Zhang, Hong Wang iD, Yin Liu, Zhifang Li, Xiangxian Feng, Xiping Luo, Wen Chen iD, Shaokai Zhang iD, Hui Yang iD, Youlin Qiao iD

Journal of Clinical Microbiology · 2026

DOI: 10.1128/jcm.01289-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Jiangong Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Northwestern Polytechnical University, Xi'an, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Genotyping Techniques. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the clinical performance of Hybribio’s 14-type HPV real-time PCR with 16/18 genotyping (HBRT-H14) and its risk stratification utility among women with normal cytology (NILM). From 2017 to 2020, a multicenter cohort enrolled 8,401 women aged 30–64 years with NILM cytology. Baseline HPV testing used HBRT-H14. Women positive for HPV 16/18 were referred for colposcopy; follow-up was annual for 3 years or until the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Analyses included 6,679 women who completed follow-up. Overall HPV positivity was 11.4%, including 2.3% HPV 16/18. Over 3 years, sensitivity and specificity of HPV positivity for CIN2+ were 92.3% (95% confidence interval [CI]: 84.2–96.4) and 89.6% (88.8–90.3). For HPV 16/18 positivity, sensitivity and specificity were 41.0% (30.8–52.1) and 98.2% (97.8–98.5). Three-year cumulative CIN2+ risk was 20.9% (15.2–28.1) for HPV 16/18-positive women, 6.6% (4.9–8.9) for other types, and 0.1% (0.04–0.2) for HPV-negative women. HBRT-H14 shows strong clinical performance for detecting CIN2+, and HPV 16/18 genotyping provides effective risk stratification among women with NILM cytology. Findings support integration of HBRT-H14 into HPV-based screening pathways with HPV 16/18 genotyping and cytology triage of other types. IMPORTANCE This multicenter prospective study evaluated the Hybribio 14 high-risk HPV real-time PCR assay (HBRT-H14) in 8,401 women with normal (NILM) cytology under guideline-based follow-up. The assay showed high clinical sensitivity and a very low risk among HPV-negative women, and HPV 16/18 genotyping provided clear risk stratification. These findings deliver large-scale, practice-oriented evidence supporting integration of HBRT-H14 into HPV-based screening pathways that use HPV 16/18 genotyping with cytology triage of other types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsHuman papillomavirus 18Human papillomavirus 16Genotyping TechniquesHumansFemaleMiddle AgedChinaAdultProspective StudiesGenotypeSensitivity and SpecificityUterine Cervical NeoplasmsUterine Cervical DysplasiaEarly Detection of CancerRisk AssessmentReal-Time Polymerase Chain ReactionColposcopy

Stichwörter der Autor:innen

cervical cancercervical intraepithelial neoplasiagenotypehigh-risk human papillomavirus testingscreening

Autor:innen und Institutionen

  • School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.
  • Department of Cancer Epidemiology and Prevention, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint L…
  • Department of Preventive Medicine, Changzhi Medical College, Changzhi, China.
  • Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou, China.
  • Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
  • School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

ORCID-Profile: Hong Wang, Wen Chen, Shaokai Zhang, Hui Yang, Youlin Qiao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Wang, H., Liu, Y., Li, Z., Feng, X., Luo, X., Chen, W., Zhang, S., Yang, H., & Qiao, Y. (2026). HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01289-25

Vancouver

Zhang J, Wang H, Liu Y, Li Z, Feng X, Luo X, et al. HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.01289-25

BibTeX
@article{Zhang2026,
  author = {Zhang, Jiangong and Wang, Hong and Liu, Yin and Li, Zhifang and Feng, Xiangxian and Luo, Xiping and Chen, Wen and Zhang, Shaokai and Yang, Hui and Qiao, Youlin},
  title = {HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  doi = {10.1128/jcm.01289-25}
}
Kostenlos starten →